原发性中枢神经系统弥漫大B细胞性淋巴瘤16例临床病理分析

目的 探讨原发性中枢神经系统弥漫大B细胞淋巴瘤(diffuse large B-cell lymphomas,DLBCL)的临床病理特点和免疫分子亚型及与预后的相关性.方法 回顾性分析16例原发性中枢神经系统DLBCL的临床表现、影像特点,采用HE染色及EliVision法观察其病理组织学特点和免疫表型特征.结果 临床上主要表现为颅内压增高、肢体乏力、视力障碍和神经精神症状,可为单发或多发性病灶;影像学上,CT示肿块多呈稍低密度阴影,MRI示T1WI呈低或等信号,T2WI呈高或等信号,强化明显,病灶周围常见明显水肿带.组织学特点为瘤细胞细胞形态较单一,弥漫浸润,瘤细胞常围绕血管形成袖套状,伴片状坏死及出血.免疫分子分型示9例DLBCL为生发中心型,7例为非生发中心型.结论 原发性中枢神经系统DLBCL是高度侵袭性淋巴瘤,为2008年WHO淋巴造血系统肿瘤分类已新增加的DLBCL亚型,具有较独特的临床病理学特点及生物学行为.好发中老年人,临床表现和影像学缺乏特异性.病理组织形态特点为瘤细胞弥漫或结节分布,以瘤细胞常围绕血管袖套状浸润为其特征性结构,可有坏死、出血;分子亚型主要为生发中心型.     

肠道非霍奇金淋巴瘤与EB病毒、p53、p21ras的相关性

目的：研究肠道非霍奇金淋巴瘤（NHL）与EB病毒（EBV）感染p53、p21^ras蛋白表达及其相关性。方法：以SABC免疫组化方法检测瘤细胞p53、p21^ras基因的表达及EBV寡核苷酸探针（EBER）原位杂交。结果：19例肠道NHL好发部位小于肠下段和结肠，以单发瘤结节多见，常伴有表面溃疡形成。经免疫组化证实3例为T细胞淋巴瘤（15.79%），16例为B细胞淋巴瘤（84.21%）。依WHO分类，T细胞淋巴瘤为外周T细胞性（2／19例）和T／NK细胞性（1／19例）。EBV－EBER原位杂交3／19例有阳性表达，均为T细胞淋巴瘤，阳性细胞占肿瘤细胞的30％－80％。B细胞淋巴瘤未见阳性。p53的表达共有12例，占全部病例的63.16%，11例有p21^ras的表达，为57.9%，有8例同时检出p53和p21^ras的表达。结论；肠道淋巴瘤以B细胞淋巴瘤多发，并以惰性为多见，如为T细胞性淋巴瘤，提示多是侵袭性，且T细胞淋巴瘤与EBV相关性较高，而B细胞淋巴瘤无相关性。p53的表达与EBV感染无明显相关性，而p21^ras的表达与EBV感染似有关系。     

富于T细胞/组织细胞的B细胞淋巴瘤的诊断

目的：探讨富于T细胞／组织细胞B细胞淋巴瘤（TCRBCL）的诊断。方法：用S－P石蜡免疫组化法检测22例依据形态学诊断的霍奇金淋巴瘤细胞和背景细胞的免疫表型。结果：4／22例是TCRBCL,3例富于T小淋巴细胞,1例富含组织细胞;瘤细胞3例呈中心母细胞样和免疫母细胞样。1例呈腔隙型细胞样,弥漫散在分布。免疫组化瘤细胞呈CD20（＋）、CD15（－）、CD30（－）、CD21（－）、vimentin(-)。背景细胞CD45RO（＋）／CD68（＋）细胞占绝对优势,为浸润细胞的70％－90％;CD20（＋）细胞散在,CD57（＋）稀少。16例为经典型霍奇金淋巴瘤（CHL）,瘤细胞为CD15（＋）（75％）、CD30（＋）（100％）、vimentin( )(19%)、CD21（－）、CD20（－）及CD45（－）,背景细胞CD45RO（＋）和CD20（＋）数量基本相等,CD57（＋）较少。1例为结节性淋巴细胞为主型霍奇金淋巴瘤（NLPHL）,瘤细胞呈CD20（＋）、CD45（＋）、CD30（－）、CD15（－）,而背景细胞中CD57（＋）较多。结论：石蜡免疫组化在TCRBCL诊断中起重要作用,而且也应用于CHL、NLPHL及TCRBCL间鉴别诊断。     

原发性中枢神经系统恶性淋巴瘤MR表现及其病理学基础

目的 研究原发性中枢神经系统恶性淋巴瘤(PCNSL)的MR表现及其病理学基础。方法 分析13例手术病理证实的原发性中枢神经系统恶性淋巴瘤的临床病理及MR表现。结果 13例中单发肿瘤4例，多发肿瘤9例，共计36个病灶。13例病变均累及幕上，其中8例病灶位于深部脑白质近脑室旁。肿瘤平均最大径为3．2cm。T1WI略低信号28个，T2WI等信号24个。28个病灶呈均匀强化。肿瘤水肿及占位效应相对较轻。2例PCNSL行MR动态增强扫描，早期强化均不明显，时间-信号强度曲线呈缓慢上升型。病理上肿瘤细胞弥漫分布，瘤细胞大小较一致，细胞质少，细胞核大，染色质颗粒粗，可见瘤细胞围绕血管呈袖套样浸润，少见明显的出血及片状坏死，未见钙化，病理均为非霍奇金淋巴瘤。结论 原发性中枢神经系统恶性淋巴瘤的病理基础决定其MR增强形态、占位程度以及肿瘤发生部位具有一定特征，运用不同的MR影像学检查方法和技术，在多数情况下可以做出术前正确诊断。     

肠道淋巴瘤与EB病毒相关性研究

目的：探讨EB病毒（Epstein-Barr virus,EBV)感染在肠道淋巴瘤发病中的意义。方法：采用EBV的DNA原位杂交及S－P法免疫组化技术（第一抗体为EBV、CD3、CD20、CD43、CD45、CD45RO、CD74等），观察24例肠道淋巴瘤患者（8例肠病相关T细胞淋巴瘤、16例黏膜相关淋巴组织B细胞淋巴瘤）EBV感染情况。以20例慢性结肠炎作为对照。结果：患者年龄21－92岁（平均52．8岁），男女之比为3．8：1。临床上均以腹痛、腹胀或便血就诊。组织病理学：T细胞淋巴瘤细胞多形性、核大，不规则，嗜血管性及大片坏死；B细胞淋巴瘤细胞中等大小，多呈圆形、椭圆形、胞质较少淡染，核稍大，核分裂象多见，可见“淋巴上皮病变”。24例淋巴瘤中检出（原位杂交及免疫组化）EBV－DNA 14例（检出率为58．3％），其中T细胞淋巴瘤EBV的检出率为75％，B细胞淋巴瘤EBV的检出率为50％（P＜0．01）。结论：肠道淋巴瘤的发生与EBV的感染有明显的相关性。     

B细胞淋巴瘤与EB病毒关系的观察

为了了解我国非免疫缺陷相关B淋巴瘤是否与EBV有关，我们采用EBVencodedsmallRNA（EBER－1）原位杂交对127例非免疫缺陷相关B淋巴瘤进行了研究。结果显示，其中8例瘤细胞核内有EBER－1的表达（中心母细胞型4例；淋巴浆细胞样型、浆细胞型、免疫母细胞型和不能分型的高度恶性B细胞淋巴瘤各1例），检出率为6．3％。这一结果与欧美的情况一致（5％左右）．但明显低于我国何杰金病（82％）及T淋巴细胞（62％）的检出率，因此提示EBV在非免疫缺陷B淋巴瘤发病中的作用是有限的，主要致病因素还有待进一步研究。     

DC/C6融合瘤苗防治C6胶质瘤的实验研究

目的：探讨DC/C6融合瘤苗防治C6胶质瘤的疗效及作用机制。方法：采用PEG化学融合方法制备融合瘤苗，应用GFAP-FITC免疫荧光检查进行瘤苗的鉴定；立体定向制备大鼠颅内C6肿瘤模型，于种瘤后5 d经尾静脉注射107融合瘤细胞、107DC以及100 μL PBS，分设为A、B、C 3组，采用Log-rank对数秩检验进行生存分析，并行肿瘤标本HE染色及抗CD8Mcab免疫组化染色。结果： 融合瘤苗GFAP-FITC免疫荧光检查阳性；Log-rank生存分析对数据进行对数秩检验，结果表明A组与B、C组进行比较均有统计学意义（P<0.01）；A组晚期死亡大鼠（>31 d）HE染色见较多的炎性细胞浸润，CD8Mcab免疫组化染色阳性。结论：DC/C6融合瘤苗能够有效的发挥抗原提呈、活化T淋巴细胞的功能，CD8+T细胞参与抗胶质瘤免疫反应。     

小B细胞恶性淋巴瘤形态学和免疫组织化学研究

目的：探讨各种小B细胞恶性淋巴瘤的形态学、免疫表型特征及其鉴别诊断。方法：对15例小淋巴细胞性淋巴瘤（SLL）、3例淋巴浆细胞性淋巴瘤（LPL）、36例滤泡性淋巴瘤（FL）、25例套细胞淋巴瘤（MCL）、7例淋巴结边缘区B细胞淋巴瘤（MZL）和30例黏膜相关淋巴细胞型结外边缘区B细胞淋巴瘤（MALT－MZL）的石蜡切片进行HE形态学观察和CD5、CD10、CD23和cyclinD1等抗体的免疫组织化学分析。结果：各种小B细胞恶性淋巴瘤在组成细胞和组织结构上各具特征；免疫表型：SLL表达CD5（82％）和CD23（80％），FL表达CD10（87％），MCL表达cyclinD1（84％）和CD5（80％），MZL／MALT－MZL和LPL均不表达CD5、CD10、CD23和cyclinD1。结论：各种小B细胞恶性淋巴瘤均是独立疾病，各具形态学和免疫表型特征，结合HE形态学观察和CD5、CD10、CD23、cyclinD1等免疫组化分析有助于正确诊断和鉴别诊断。     

原发性心脏恶性肿瘤9例临床病理分析

目的；分析原发性心脏恶性肿瘤（PCMT）的发病学特点、病理组织类型及形态学基础。方法：应用HE染色，组化及免疫组化标记对9例PCMT进行了形态学观察，并对其临床资料作了分析。结果：根据形态学发现和免疫组化结果，9例PCMI可分为心脏恶性间皮瘤（3例）、血管肉瘤（2例）、B细胞淋巴瘤（2例）、心包胸腺瘤（1例）及交界性上皮样血管内皮瘤（1例）。结论：PCMT和见，多于中年男性，好发于心房，多数恶性肿瘤预后差，肿瘤类型多，形态结构复杂，免疫组化标记对确定肿瘤起源很有帮助，早期发现、准确诊断与局部肿瘤全切除，对肿瘤的治疗和预后分析非常重要。     

间变性大细胞淋巴瘤形态学及免疫表型观察

目的：探讨间变性大细胞淋巴瘤（ALCL）的形态学和免疫表型特征。方法：对6例ALCL和2例弥温性大B细胞淋巴瘤（DLBCL）进行形态学和免疫组织化学染色（ABC法）观察。结果：6例ALCL中，普通型2例、淋巴组织细胞型2例、ALK－变型2例，均可见单型性或多形性的标志性大细胞。普通型和ALK－变型大细胞沿淋巴窦内生长，而淋巴组织细胞型大细胞则呈散在分布；2例DLBCL形态上颇似ALCL；6例ALCL均为T细胞，CD30＋，儿童患者共同表达ALK＋和EMA＋，年长者则ALK－和EMA－。2例DLBCL均为B细胞，ALK＋、CD30－和EMA－。结论：不论何型ALCL，均可见CD30＋的标志性大细胞，淋巴窦内生长多见于普通型和ALK－变型。ALCK均为T细胞，儿童常有ALK和EMA共同表达，年长者则ALK和EMA－。DLBCL的免疫表型不同于ALCL。     

原发性中枢神经系统淋巴瘤2例临床病理分析并文献复习

目的探讨原发性中枢神经系统淋巴瘤(primary central nervous system lymphoma,PCNSL)的临床特点、病理诊断、治疗及预后。方法对2例PCNSL进行免疫组化染色并复习相关国内外文献。结果 2例PCNSL,1例为间变性大细胞型-T细胞来源,另1例为弥漫性大B细胞型,HIV均阴性。PCNSL临床表现无特异性,颅内压增高、精神失常为常见症状,影像检查缺乏特征性改变,免疫表型以B细胞为主(87.5%～98%),大剂量氨甲蝶呤联合全脑放疗缓解率高。结论 PCNSL术前难以诊断,需依赖病理检查确诊,治疗困难,预后差。     

骨小细胞恶性肿瘤34例病理形态学研究

目的 研究骨小细胞恶性肿瘤(SCMT)的病理形态和免疫组化特点。方法 应用免疫组化SP法对34例SCMT进行组织学观察。结果 34例SCMT中22例为弥漫型非霍奇金恶性淋巴瘤，其中21例B细胞性，1例T细胞性；瘤组织表达CD45(LCA)、CD20(L26)或C1345RO(UCHL—1)。7例浆细胞肿瘤，其中5例为多发性骨髓瘤、2例为孤立性浆细胞瘤，表现为单一的不同分化程度的肿瘤性浆细胞；免疫组化示6例CD38( )。2例Ewing肉瘤显示排列密集、大小较一致的圆形细胞；肿瘤表达CD99和Vim。1例小细胞骨肉瘤，肿瘤由丰富密集的小细胞和网格状的骨样组织组成，瘤细胞Vim阳性。1例间叶性软骨肉瘤示富于血管的圆形或梭形细胞和透明软骨；瘤细胞表达Vim，软骨细胞表达S—100蛋白。1例小细胞癌示小细胞紧密片巢状排列，表达CK和EMA。结论 骨SCMT组织学类型各有不同的病理形态和免疫组化特征，结合临床和X线表现可作出正确的病理诊断。     

Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification

The recent WHO classification of non-Hodgkin's lymphoma is based on the morphology and immunohistochemical expression of the lymphoma cells and to a lesser extent, on the molecular and cytogenetic findings. Fifty-three cases of non-Hodgkin's lymphoma were included in the study. Of these, seven cases were primary extra nodal lymphomas. Twenty two patients had peripheral blood and/or bone marrow involvement. A detailed morphological assessment was done and classified using the International working formulation. The two most common types encountered were diffuse large cell lymphoma and small lymphocytic lymphoma. Immunohistochemistry was done using labeled streptavidin-biotin peroxidase complex with CD3, CD20, CD15, CD30, CD 45 (leukocyte common antigen), Cyclin D1, EMA (epithelial membrane antigen). 38 cases (72%) showed B cell expression and 12 cases (22.5%) showed T cell expression. Three cases did not express either marker. B-cell diffuse large cell lymphoma (26%) was found to be the predominant B cell non-Hodgkin's lymphoma. The commonest T-cell lymphoma was T lymphoblastic lymphoma (67%) followed by peripheral T cell angioimmunoblastic lymphoma (25%). Immunohistochemistry is a useful and necessary diagnostic modality and helps subdivide prognostically different types of non-Hodgkin's lymphoma.     

Primary CNS lymphomas. Morphology and diagnosis

Diagnostically primary central nervous system lymphomas (PCNSL) have to be differentiated from glioblastoma and brain metastases. Histologically the overwhelming majority of PCNSL is represented by diffuse large B-cell lymphomas, in this series with a BCL6 expression in 80% of the cases detected by immunohistochemistry. Stereotactic biopsy is the method of choice in establishing the definite diagnosis and intraoperative smear cytology will detect the lymphoid blasts. To confirm the B-cell lineage, immunohistochemistry is needed (CD20, CD79a). Small reactive T-lymphocytes and monohistiocytic cells and activated "microglia" are found within and at the periphery of PCNSL foci. The infiltrated brain tissue shows partially pleomorphic reactive astrocytes that can be confused with neoplastic astrocytes, especially in small specimens. In contrast to high-grade gliomas, however, PCNSLs do not show endothelial proliferations. Subtypes or variants of diffuse large B-cell lymphomas can also be observed in cases of PCNSL: the anaplastic variant with large multinucleated tumour cells resembling Reed-Sternberg cells, T-cell rich B-cell lymphoma and intravascular B-cell lymphoma with primary manifestation within the brain or the spinal cord. HIV/AIDS-associated PCNSLs are characterised by large plasmoblastic or small Burkitt-like cells and tumour necrosis. Primary leptomeningeal large B-cell lymphomas do occur very rarely and are diagnosed by cerebrospinal fluid cytology.     

原发淋巴结边缘区淋巴瘤临床病理分析

目的：研究淋巴结MZL形态特征、诊断要点和鉴别诊断，为临床治疗和预后提供依据，方法：采用常规制片、免疫组化ABC法标记，光镜观察。结果：10例淋巴结MZL男性6例，女性4例，以淋巴结缓慢增大为特征，而无肝脾肿大，外周血未见异常。病理形态分为：边缘区增生型2例，结节型4例，弥漫型2例和母细胞样型2型。细胞类型：CCL细胞型5例，MBC型6例，淋巴浆细胞型2例，母细胞样型2例，10例均经免疫组化证实。结论：淋巴结MZL与MALT型淋巴瘤形态、免疫表型和起源相似。由于淋巴结组织结构特点，MZL有特殊性。     

Diffuse large B-cell lymphoma and its variants

According to the World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues, diffuse large B-cell lymphoma comprises about 40% of adult cases of non-Hodgkin s lymphoma. It consists of the following morphological variants: 1) centroblastic (with or without multilobulated nuclei); 2) immunoblastic (>90% of immunoblasts); 3) T cell/histiocytes rich; and 4) anaplastic. Rare morphological variants plasmablastic type, mediastinal (thymic) diffuse large B-cell lymphoma, intravascular, and primary effusion B-cell lymphoma are considered distinct variants of diffuse large B-cell lymphoma due to their unique topographic presentation and clinical behavior, as well as immunophenotypic and genetic characteristics. T-cell/histiocyte-rich B-cell lymphoma is morphologically characterized by up to 25% of large neoplastic B cells and 75-90% of reactive, non-neoplastic T cells. Mediastinal (thymic) diffuse large B-cell lymphoma is considered a subtype of diffuse large B-cell lymphoma arising in the mediastinum, with distinctive morphological, immunohistochemical, genotypic, and clinical features. Mediastinal diffuse large B-cell lymphoma is an aggressive disease with poor outcome, which probably originates from thymic B cells at the terminal stage of differentiation. During the 1997-2001 period, 720 patients were diagnosed with non-Hodgkin s lymphoma in our institution. Out of 101 (14%) patients with diffuse large B-cell lymphoma, 17 had T-cell-rich B-cell lymphoma and their median survival was less than 20 months, with no difference regarding sex, bone marrow involvement, CD30 positivity, or histiocytic component of the tumor. Twenty out of 101 patients had mediastinal B-cell lymphoma and their median survival was 21 months, with sex or degree of necrosis of the involved lymph node having no impact on survival. We studied the frequency of bcl-2 gene rearrangement in fusion with immunoglobulin receptor gene of t(14;18) and found no such event among 20 of our patients with mediastinal diffuse large B-cell lymphoma. Despite extensive efforts and constant progress in our understanding of non-Hodgkin s lymphoma pathogenesis, the diffuse large B-cell lymphoma group remains heterogeneous entity awaiting further pathological and clinical stratification.     

Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis

Recent studies have exploited an antibody directed against programmed death 1 expressed by follicular helper T-cells in the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma. We had previously described clinically relevant, variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma and, in this study, sought to address the diagnostic utility of programmed death 1 in comparison with CD57 in variant nodular lymphocyte predominant Hodgkin lymphoma. Immunohistologic staining for programmed death 1 was carried out on biopsies of 67 patients with variant nodular lymphocyte predominant Hodgkin lymphoma. Thirty-four additional cases of nodular lymphocyte predominant Hodgkin lymphoma with associated diffuse areas, de novo T-cell and histiocyte-rich large B-cell lymphoma, and lymphocyte-rich classic Hodgkin lymphoma were also studied. Our results show that programmed death 1 positivity was found in the majority of nodular lymphocyte predominant Hodgkin lymphoma cases with a classic nodular architecture (87%) as compared with 50% for CD57 and was particularly helpful in identifying extranodular large atypical cells. Nodular lymphocyte predominant Hodgkin lymphoma with diffuse areas showed a gradual decrease in programmed death 1 reactivity from nodular to diffuse areas, although a significant proportion (40%-50%) of cases retained programmed death 1 positivity also in diffuse areas. In addition, T-cell and histiocyte-rich large B-cell lymphoma and lymphocyte-rich classic Hodgkin lymphoma displayed programmed death 1 positivity in a significant subset of cases (33%-40%). In conclusion, our study supports the utility of programmed death 1 in the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma and shows greater sensitivity of staining of programmed death 1 as compared with CD57 across all variants of nodular lymphocyte predominant Hodgkin lymphoma. Loss of programmed death 1 reactivity did not correlate with diffuse areas, progression, or the ability to differentiate nodular lymphocyte predominant Hodgkin lymphoma from T-cell and histiocyte-rich large B-cell lymphoma. These findings suggest the need for continued vigilance in the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma and its immunoarchitectural variants as well as related lymphomas in their differential diagnosis.     

脾边缘区B细胞淋巴瘤临床病理和免疫组化研究

目的：研究脾边缘区B细胞淋巴瘤（SMZL）临床病理和免疫组化特征,为临床治疗和预后提供依据。方法：组织常规制片,应用ABC免疫组化法标记,光镜观察。结果：6例SMZL以脾肿大为主要临床特征,无全身淋巴结肿大,仅1例外围血和骨髓内查出异形淋巴细胞。病理形态显示结节型4例,弥漫型2例,细胞呈现CCL细胞型3例,MBC型2例,淋巴浆细胞型1例,6例均经免疫组化证实。结论：SMZL与MALT型淋巴瘤／淋巴结边缘区B细胞淋巴瘤组织形态和免疫表型相似,但并不完全相同,SMZL与其它B细胞起源的淋巴瘤临床治疗和预后亦不相同。     

皮下脂膜炎性T细胞淋巴瘤临床病理分析

目的分析皮下脂膜炎性Ｔ细胞淋巴瘤的病理形态和生物学行为特点,并对其分类命名作一探讨。方法用ＨＥ和免疫组化ＡＢＣ方法对４例原发并定位于皮下脂肪组织中的Ｔ细胞淋巴瘤进行临床病理学和免疫组织化学观察。结果４例病人均表现１～３ｃｍ的皮下结节,伴高热,临床经过凶猛,短期死亡。组织学上以肿瘤细胞（ＣＤ４５ＲＯ阳性）浸润脂肪小叶之间及大量豆袋细胞（ｂｅａｎｂａｇｃｅｌ,ＣＤ６８阳性）为特征。结论皮下脂膜炎性Ｔ细胞淋巴瘤是一种恶性度很高的外周Ｔ细胞淋巴瘤。     

滤泡树突状细胞肉瘤的临床病理观察

目的 探讨和分析滤泡树突状细胞肉瘤(FDCS)的临床病理特点及鉴别诊断.方法 应用组织学、免疫组织化学(EnVision法)标记及EBER原位杂交,对8例FDCS进行临床和组织病理学分析,并复习相关文献.结果 8例FDCS中男性5例,女性3例,平均年龄50岁.发生部位淋巴结4例,扁桃体、鼻咽部、肝、脾各1例.组织学:瘤组织呈席纹状、束状、弥漫性、旋涡状或结节状,肿瘤细胞呈合体样,境界不清,胞质较丰富,均质嗜伊红或细颗粒状,核呈卵圆形、短梭形或圆形,染色质稀疏或呈空泡状、点彩状,核仁明显,核分裂象多少不等,肿瘤细胞间见有散在淋巴细胞混杂.间质内可见假血管腔及血管周围淋巴鞘现象.其中肝脏1例以大量小淋巴细胞弥漫分布为背景,梭形或卵圆形的瘤细胞散在分布其中,瘤细胞核染色质细腻,部分区域细胞有轻度异形,核不规则、空泡状,有核仁.免疫组织化学瘤细胞均表达CD21、CD35、clusterin,部分表达CD68、上皮细胞膜抗原、S-100及内皮生长因子受体,Ki-67不同程度表达.EBER两例表达.结论 FDCS是一种非常少见的恶性肿瘤,易复发和转移,明确诊断需要结合病理形态学和免疫表型.